SPOCK: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor after Aromatase Inhibitor and CDK inhibition. A Phase II, open label, interventional trial using gene expression based biomarkers of estrogen activation in advanced

General Information Age Group Adults Status Recruiting Protocol Number NCT04965688 Background Information Gene expression profiling has become commonly used in early stage breast cancer but is not commonly used in metastatic breast cancer. Therefore, we have developed gene expression based biomarkers of estrogen activation in advanced breast cancer and of MTOR activation in breast cancer. The purpose of this study is to determine if treatment based on these biomarkers can improve progression free survival by matching treatments to tumors with active pathways targeted by those treatments. This study is funded in part by the National Institutes of Health and the Beckman Research Institute in the City of Hope. Offered At Inova Schar Cancer Institute 8081 Innovation Park Drive Fairfax, VA 22031 A Department of Inova Fairfax Hospital Eligibility Information Histologic diagnosis of breast cancer Metastatic or incurable Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor Progression while on or within 6 months of stopping the CDK4/6 inhibitor At least one lesion amenable to percutaneous biopsy that is not a purely scleroticbone lesion Age 18 or greater Additional eligibility in protocol. Ineligibility Information Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine Comorbid disease other than breast cancer with a life expectancy of less than 2 years Cancer other than breast cancer that is expected to need treatment within 2 years Platelets < 100,000/microliter INR > 1.5 Additional ineligibility in protocol For additional information, please see: https://www.clinicaltrials.gov/ct2/show/NCT04965688 Contact Information Contact Name Lindsey Tishman Contact Phone 571-472-0633 Contact Email Send Email